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Abstract: While several marine polar lipids (PL) have exhibited cardioprotective properties through
their effects on the platelet-activating factor (PAF) pathways, salmon PL have not been tested so
far. In this study, the antithrombotic activities of salmon PL were assessed in human platelets
and the structural characterisation of bioactive salmon PL was performed by GC-MS and LC-MS
analyses. PL from fillets of Irish organic farmed salmon (Salmo salar) were extracted and separated
into several lipid subclasses by thin-layer chromatography (TLC), while their fatty acid profile
was fully characterised by GC-MS. Salmon total lipids (TL), total neutral lipids (TNL), total polar
lipids (TPL), and each PL subclass obtained by TLC were further assessed for their in vitro effects
towards PAF-induced and thrombin-induced platelet aggregation in human platelets. Salmon PL
exhibited antithrombotic effects on human platelet aggregation, mostly through their strong inhibitory
effects against the PAF pathway with IC50 values comparable to other marine PL, but with lower
effects towards the thrombin pathway. PL fractions corresponding to phosphatidylcholine and
phosphatidylethanolamine derivatives exhibited the most potent anti-PAF effects, while LC-MS
analysis putatively elucidated their structure/function relationship. Several diacyl-PC/PE and
alkyl-acyl-PC/PE species containing mostly docosahexaenoic acid at their sn-2 glycerol-backbone
may be responsible for the bioactivity. The data presented suggests that salmon contains PL with
strong antithrombotic bioactivities.
Keywords: salmon; polar lipids; platelet aggregation; platelet-activating factor (PAF); thrombin;
antithrombotic; LC-MS; GC-MS; phosphatidylcholine; phosphatidylethanolamine; polyunsaturated
fatty acids (PUFA); docosahexaenoic acid (DHA)
1. Introduction
Over the past few decades, extensive research has been conducted concerning the
anti-inflammatory and cardioprotective properties of fish oils and marine products. In the majority
of these studies, most of the anti-inflammatory activities of fish oils were attributed to the ω3
polyunsaturated fatty acids (PUFA) content, including the presence of eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA), which are abundant in marine products [1]. It has been proposed
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that diets with a 1:1 ratio of ω6/ω3 PUFA may reduce the risk of many of the chronic diseases that
are highly prevalent in Western societies and developing countries, including cardiovascular diseases
(CVD) [2].
However, it is now well-established that more complex mechanisms underlie the beneficial effects
of fish and fish oil consumption and administration of marine products that go far beyond the ω3
PUFA/eicosanoids-related mechanisms [3]. Other lipid constituents are also present in fish and fish
oils that have different metabolic effects after absorption with distinct biological activities [3].
Recent research has highlighted the well-documented and promising beneficial effects of
marine polar lipids (PL) towards inflammation related disorders, through a plethora of beneficial
bioactivities [3,4]. These beneficial effects are not only limited to their superior incorporation into cell
membranes and plasma lipoproteins, including high-density lipoprotein (HDL), but also include
the bioavailability of their ω3 fatty acids, and mainly to their reported anti-inflammatory and
antithrombotic activities through mechanisms such as the inhibition of the platelet-activating factor
(PAF) pathway and the modulation of PAF metabolism [3,4].
PAF is a potent inflammatory mediator implicated in several inflammatory manifestations such as
atherosclerosis and CVD, glomerulosclerosis and renal disorders, cancer, HIV-infection comorbidities,
etc. [3,5–8]. Even though specific PAF antagonists and synthetic molecules have exhibited promising
results in such disorders, the most prominent beneficial effects have been found in PL derived from
several foods [3,9,10], including marine products without any reported side effects thus far [3,10–12].
These marine PL exhibit anti-inflammatory and antithrombotic activities through both inhibiting
PAF activities and modulating its metabolism towards homeostatic reduction of PAF levels [3,4,13].
Through these bioactivities, marine PL have exhibited potent anti-atherogenic and cardioprotective
effects in vitro and in vivo [3,10–18].
Salmon PL have yet to be assessed for their effects towards the PAF pathway. Therefore, for the first
time this study examines the putative anti-inflammatory, antithrombotic, and cardioprotective effects of
salmon PL derived from Irish organic farmed salmon, by assessing their inhibitory effects towards the
PAF pathway and the thrombin pathway of platelet aggregation in human platelet-rich plasma (hPRP).
In addition, these lipids were further separated into PL subclasses and structurally characterised by
GC-MS and LC-MS analysis, in order to elucidate the structure and function relationship of salmon PL
with strong antithrombotic and cardioprotective properties.
2. Results
2.1. TL, TPL, and TNL Content of Salmon Fillet Samples
Total lipids (TL) of all salmon samples (n = 6) were extracted and separated into total neutral
lipids (TNL) and total polar lipid (TPL). The obtained amounts of TL, TPL, and TNL (expressed as
g of lipids per 100 g of fish tissue) are given in Table 1. Salmon is categorised as an oily fish species
and thus data of TL levels in this fish are higher than other fish species, which is in accordance with
the literature [3]. In addition, the majority of lipids extracted were neutral, since the neutral lipid
fraction (TNL) contributes approximately 60–84% of the TL, whereas the TPL fraction contributes
approximately to the 16–40% of the TL.
2.2. TLC Analysis of Irish Organic Farmed Salmon Fillets Total Polar Lipids
Salmon TPL were further separated into PL subclasses and fractions by preparative TLC analysis.
It was found that within the salmon TPL extracts several phospholipid species exist as depicted in the
TLC bands (Figure 1A). PL fractions 1–6 have similar Rf values to those of lyso-phosphatidylcholine
(L-PC), sphingomyelin (SM), phosphatidylcholine (PC), lyso-phosphatidylethanolamine (L-PE),
phosphatidylethanolamine (PE), and cardiolipin (CL) respectively (Figure 1A).
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Table 1. Content of TL, TPL, and TNL of Irish organic farmed salmon (Salmo salar) fillets and the
inhibitory effect of these lipids towards the PAF/thrombin-pathway of platelet aggregation in hPRP.
TL TNL TPL
Lipid Content * (g) ± SD 5.51 ± 1.90 4.66 ± 2.08 0.86 ± 0.36
IC50 † (µg) ± SD towards PAF inhibition 170 ± 32 432 ± 44 45 ± 22
IC50 † (µg) ± SD towards thrombin inhibition 451 ± 56 682 ± 62 382 ± 39
* Expressed as mean values of g of lipids per 100 g of salmon fillet (mean ± SD, n = 6); † IC50 values reflect the
inhibitory strength of each lipid sample towards PAF-induced platelet aggregation in hPRP and is expressed as
mean values of µg of lipids in the aggregometer cuvette that causes 50% of inhibition on PAF-induced platelets
aggregation in hPRP ± standard deviation. TL: total lipids; TPL: total polar lipids; TNL: total neutral lipids; PAF:
platelet-activating factor; hPRP; human platelet-rich plasma; SD: standard deviation.
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Figure 1. TLC analysis of the TPL of Irish organic farmed salmon fillets and the biological activity
of each PL subclass towards PAF-induced platelet aggregation in hPRP. (A): Typical profile of the PL
separation of salmon fillet on preparative TLC (Silica G). The elution syste used for the separation of
the TPL was chloroform:methanol:water 65:3 :6 (v/v/ ). L: Polar lipids; E: mixture of standard PL
from egg; Lyso-PC: lyso-phosphatidylcholine; SM: sphingomyeli hatidylcholine; Lyso-PE:
lyso-phosphatidylethanolamine; PE: phosphatidylethanolamin ; L: cardiolipin; TLC; thin-layer
chromatography. (B): Biological activities of the PL subclasses of the TLC bands towards PAF-induced
platelet aggregation in hPRP. The results reflect the inhibitory strength of each lipid sample and are
expressed as mean values of IC50 (µg of lipids in the aggregometer cuvette that causes 50% inhibition
of PAF-induced aggregation of hPRP); The low IC50 value indicates strong inhibition of PAF-induced
aggregation of hPRP; Lipid fractions of TLC bands 1 and 4 (corresponding to Lyso-PC and Lyso-PE)
did not exhibit these bioactivities. hPRP: human platelet-rich plasma; PAF: platelet-activating factor;
PL: polar lipids; TPL: total polar lipids.
2.3. Inhibitory Effect of Irish Organic Farmed Salmon Fillets Polar Lipids Towards Aggregation of Human
Platelet-Rich Plasma (hPRP)
The in vitro study demonstrates that all salmon TPL extracts exhibited potent inhibition of
PAF-induced aggregation of hPRP at very low doses, while much higher doses of these lipids were
needed to inhibit the thrombin-induced aggregation of hPRP (Table 1). A representative chart for the
in vitro effect of salmon TPL towards the PAF pathway of platelet aggregation of hPRP is depicted in
Figure 2.
IC50 values reflect the inhibitory strength of each salmon TPL sample, because a low IC50 value
indicates stronger inhibition of PAF-induced/thrombin-induced aggregation for a given salmon TPL
concentration. Salmon TPL exhibited much higher inhibitory effects towards the PAF pathway than
that of TL and TNL (Table 1). Thus, the intermediate IC50 value of the anti-inflammatory effect of the
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salmon TL can be attributed to the presence of both salmon TPL (with low IC50 values and thus higher
inhibitory effects against PAF) and the salmon TNL (with higher IC50 value and thus lower inhibitory
effects against PAF) within the TL fraction.Mar. Drugs 2018, 15, x FOR PEER REVIEW  4 of 19 
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The mean IC50 value of the inhibitory effect of all the salmon TPL extracts towards PAF-induced
aggregation was 45± 22 µg of TPL in the aggregometer cuvette (Table 1). This IC50 value is comparable
with relative IC50 values of bioactive PL extracts from other fish species, but also from other food
samples, which exhibited similar anti-inflammatory effects towards PAF-induced activation and
aggregation of platelets [3,4,13,16–22]. Similarly, the TPL fraction exhibited the strongest inhibitory
effect towards the thrombin pathway of platelet aggregation in hPRP, while higher amounts of both
TL and TNL fractions were needed for such inhibition (Table 1). Thus, the intermediate IC50 value of
the antithrombotic effect of the salmon TL can be similarly attributed to the presence of both salmon
TPL (with low IC50 values and thus higher inhibitory effects against thrombin) and the salmon TNL
(with higher IC50 value and thus lower inhibitory effects against thrombin) within the TL fraction.
The mean IC50 value of the inhibitory effect of all the salmon TPL extracts towards thrombin-induced
aggregation was 382 ± 39 µg (Table 1).
Nevertheless, the anti-thrombin effect of all salmon lipid samples tested (TL, TPL, and TNL
respectively) were much lower than that of their effect on the PAF-induced platelet aggregation,
as depicted by their much higher IC50 values against thrombin-induced platelet aggregation.
This difference is much more intense in the TPL fraction where the IC50 values against thrombin
are approximately one order of magnitude higher than that against PAF, implying that the in vitro
antithrombotic effects of salmon PL mostly occur through their potent inhibitory effect on the PAF
pathway of platelet aggregation in hPRP.
Furthermore, the PL subclasses in each of the TLC bands, which were obtained by the TLC
separation of the TPL, were also tested for their ability to inhibit PAF-induced platelet aggregation
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of hPRP. The IC50 values of the bioactive lipid fractions in each TLC band are shown in Figure 1B.
The TPL extract of salmon exhibited inhibitory properties, that are attributed to almost all the polar
lipid fractions (Bands 2, 3, 5, and 6) apart from lipid fractions 1 and 4 that did not exhibit such an effect
(Figure 1B). None of the fractions exhibited had any aggregatory properties in hPRP. PL fractions 3
and 5, which have similar Rf values to those of PC and PE exhibited the most potent inhibitory effect
towards PAF-induced aggregation of hPRP. These results are in accordance with previous reported
IC50 values against PAF for these PL subclasses (PC and PE) in the same TLC bands obtained from the
TLC analysis of TPL extracts from several other fish species [3,4,13,15,17].
2.4. GC-MS Analysis of Salmon Polar Lipids
In all salmon TPL samples, PUFA were the most abundant fatty acid class followed by saturated
fatty acids (SFA) and monounsaturated fatty acids (MUFA) (Table 2). More specifically, salmon TPL
contains high amounts of ω3 PUFA with the most abundant ω3 fatty acids being the EPA (20:5ω3)
and the DHA (22:6ω3) (Table 2). The most abundantω6 fatty acids in salmon TPL were arachidonic
acid (ARA; 20:4ω6) and linoleic acid (LA; 18:2ω6). The most abundant MUFA was oleic acid (18:1 c9)
and the most abundant SFA was palmitic acid (16:0) and stearic acid (18:0). Interestingly, theω3 fatty
acid content was significantly higher than that of ω6 fatty acids, thus the ratio of ω6/ω3 was found to
be approximately 1/2.5 (Table 2), which differs positively from the suggested value of 1 for this ratio.
Table 2. Fatty acid profile of the total polar lipids (TPL) of Irish organic farmed salmon fillets expressed
as a percentage of total fatty acids (%FA) derived from the TPL and expressed as mg/kg of salmon
fillet (mean ± SD, n = 3).
Fatty Acids % FAs mg/kg of Salmon
12:0 0.018 ± 0.001 1.3574 ± 0.096
14:0 2.107 ± 0.138 159.71 ± 15.33
14:1ω7 c9 0.098 ± 0.008 7.4086 ± 0.806
16:0 22.56 ± 0.658 1711.2 ± 95.30
16:1ω7 c9 1.992 ± 0.659 151.63 ± 55.74
18:0 6.331 ± 0.040 480.22 ± 38.98
18:1ω9 c9 13.31 ± 0.904 1009.8 ± 122.7
18:2ω6 c9, c12 6.938 ± 0.378 526.18 ± 50.54
18:2ω6 c11, c14 0.113 ± 0.008 8.5675 ± 0.275
18:3ω6 c6, c9, c12 0.047 ± 0.014 3.5902 ± 1.186
18:3ω3 c9, c12, c15 2.139 ± 0.123 161.78 ± 5.438
18:4ω3 c6, c9, c12, c15 0.695 ± 0.047 200.20 ± 257.0
20:0 0.157 ± 0.053 9.4081 ± 0.545
20:1ω9 c9 3.512 ± 0.208 265.62 ± 8.865
20:2ω6 c11, c14 0.890 ± 0.114 67.497 ± 10.30
20:3ω9 c5, c8, c11 0.771 ± 0.042 58.644 ± 7.951
20:4ω6 c5, c8, c11, c14 2.091 ± 0.120 158.41 ± 13.02
20:4ω3 c8, c11, c14, c17 0.347 ± 0.127 26.416 ± 10.45
20:5ω3 c5, c8, c11, c14, c17 10.02 ± 0.344 765.56 ± 37.49
22:1 c11 4.458 ± 0.590 339.03 ± 59.87
22:5ω6 c4, c7, c10, c13, c16 0.424 ± 0.116 32.176 ± 9.535
22:6ω3 c4, c7, c10, c13, c16, c19 12.94 ± 0.418 981.66 ± 92.63
Total SFA 32.54 ± 0.211 2425.5 ± 160.0
Total MUFA 24.08 ± 0.639 1835.3 ± 187.9
Totalω7 FA 2.448 ± 0.069 186.24 ± 58.80
Totalω9 FA 17.59 ± 0.927 1334.1 ± 187.9
Total PUFA 37.85 ± 0.527 3005.9 ± 366.4
Totalω3 PUFA 26.42 ± 0.419 2135.6 ± 317.2
Totalω6 PUFA 10.50 ± 0.131 796.43 ± 59.56
ω6/ω3 0.37 ± 0.08
TPL: total polar lipids; FA: fatty acids; SFA: saturated fatty acid; MUFA: monounsaturated fatty acid; PUFA:
polyunsaturated fatty acid; ND: not detected.
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In relation to the GC-MS analysis of the PL subclasses of each TLC band, the most abundant fatty
acids found in band 3 (PC) were theω3 fatty acids EPA (20:5ω3) and DHA (22:6ω3) from the PUFA,
palmitic acid (16:0) and stearic acid (18:0) from the SFA, and oleic acid (18:1 c9), and palmitoleic acid
(16:1 c9) from the MUFA (Table 3). Notably, theω3 fatty acid content of salmon PC was significantly
higher than that of ω6 fatty acids (Table 3), and thus the relative ratio of ω6/ω3 in salmon PC was
found to be approximately 1/5, which is much lower than the value of 1 for this ratio, but was higher
in comparison to the relative ratio found in the TPL.
In addition, similarly to the salmon PC subclass, the most abundant fatty acids found in band 5
(PE) were theω3 fatty acid EPA from the PUFA, palmitic acid (16:0) and stearic acid (18:0) from the
SFA, and oleic acid (18:1 c9) and palmitoleic acid (16:1 c9) from the MUFA (Table 3). However, theω3
fatty acid DHA was not detected in the PE subclass of salmon. Theω3 fatty acid content of salmon PE
was also higher than that of its content in ω6 fatty acids (Table 3), however the subsequent relative
ratio ofω6/ω3 for this PL subclass had a value of 1/1.5 that even though it was still lower than the
value of 1/1 for this ratio, it was however higher than the relative ratio of both salmon TPL and PC.
Table 3. Fatty acid profile of the lipid fractions of PC and PE derived from salmon TPL, expressed as a
percentage (%) of TPL fatty acids of salmon (mean ± SD, n = 3).
Fatty Acids PC PE
12:0 0.060 ± 0.004 0.034 ± 0.012
14:0 2.210 ± 0.212 5.424 ± 0.198
16:0 30.00 ± 0.488 20.76 ± 0.947
16:1ω7 c9 2.211 ± 0.121 1.883 ± 0.054
16:4ω3 c6, c9, c12, c15 0.290 ± 0.023 ND
18:0 8.171 ± 0.568 9.157 ± 0.543
18:1ω9 c9 7.937 ± 0.365 11.40 ± 0.044
18:1ω5 c13 2.369 ± 0.003 2.181 ± 0.269
18:2ω6 c9,c12 3.578 ± 0.068 2.298 ± 0.036
18:3ω3 c9, c12, c15 1.470 ± 0.033 1.562 ± 0.044
20:0 0.133 ± 0.029 0.945 ± 0.200
20:1ω9 c9 0.408 ± 0.011 1.054 ± 0.012
20:1ω7 c13 1.213 ± 0.097 6.670 ± 0.832
20:2ω6 c11, c14 0.516 ± 0.016 0.408 ± 0.001
20:3ω9 c5, c8, c11 0.252 ± 0.008 ND
20:4ω6 c5, c8, c11, c14 2.128 ± 0.139 1.012 ± 0.089
20:4ω3 c8, c11, c14, c17 0.785 ± 0.007 1.233 ± 0.030
20:5ω3 c5, c8, c11, c14, c17 9.289 ± 0.729 2.936 ± 0.123
22:1ω9 c11 2.203 ± 0.193 7.913 ± 0.716
22:5ω6 c4, c7, c10, c13, c16 2.553 ± 0.020 ND
22:6ω3 c4, c7, c10, c13, c16, c19 21.57 ± 1.407 ND
SFA 40.58 ± 1.301 36.32 ± 1.501
Total MUFA 16.34 ± 0.398 31.59 ± 0.247
Totalω7 FA 3.424 ± 0.218 2.937 ± 0.041
Totalω9 FA 10.80 ± 0.175 20.36 ± 0.747
Total PUFA 42.43 ± 2.172 9.449 ± 0.233
Totalω3 PUFA 33.41 ± 2.219 5.731 ± 0.109
Totalω6 PUFA 6.222 ± 0.054 3.718 ± 0.125
ω6/ω3 0.186 ± 0.075 0.649 ± 0.053
PC: phosphatidylcholine; PE: phosphatidylethanolamine; TPL: total polar lipids; FA: fatty acids; SFA: saturated
fatty acid; MUFA: monounsaturated fatty acid; PUFA: polyunsaturated fatty acid; ND: not detected.
2.5. LC-MS Analysis of Salmon Polar Lipids
Salmon TPL and the most bioactive TLC fractions against the PAF pathway, PC and PE, were
further analysed by LC-MS. Characteristic chromatograms of the HPLC separation (by using a C18
reversed phase column) for both PE and PC TLC fractions are depicted in Figure 3. The HPLC analysis
of PE revealed 6 major peaks (Figure 3A), while the HPLC analysis of PC revealed 9 major peaks
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with specific retention times (Figure 3B). The HPLC was equipped with a Q-TOF mass spectrometer,
therefore MS analysis was also conducted simultaneously with the HPLC separation for each one
of these peaks. Thus, specific MS spectra were obtained for each peak and several structures for
these PC and PE moieties are proposed. Characterisation of these molecules was based on the
acquired m/z values of the negative ions [M − H]− for PE and the demethylated negative ions
[M − CH3]− for PC [23], and further verified by using the LIPID MAPS: Nature Lipidomics Gateway
(www.lipidmaps.org), based on the lowest delta values during identification, in combination with
their fatty acids contents that were acquired by both GC-MS and LC-MS analyses.
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Figure 3. Representative HPLC chromatograms of salmon PL LC-MS analysis. (A) Depicts a
representative chromatogram of the TLC fraction corresponding to salmon phosphatidylethanolamine
(PE) derivatives, whereas (B) depicts a representative chromatogram of the TLC fraction
corresponding to salmon phosphatidylcholine (PC) derivatives. Analysis was performed using a
HPLC (Agilent 1260 series) equipped with Q-TOF mass spectrometer (Agilent 6520). The column used
for the separations was an Agilent C18 Poroshell 120 column (2.7 µm, 3.0 × 150 mm). The composition
of mobile phase (A) was 2 mM ammonium acetate in water and 2 mM ammonium acetate in 95%
acetonitrile for mobile phase (B). Chromatographic separation was performed by gradient elution
starting with 60% B for 1 min, then increasing to 90% B over 2.5 min. Subsequently, 90% B was held
for 1.5 min and increased afterward to 100% over 5 min. Then, 100% B was held for 4 min, reducing
afterward to 60% B over 0.5 min and hold for 1 min until the next run. The mobile phase flow rate was
0.3 mL/min until 5 min elapsed, increasing up to 0.6 mL/min until 10 min had elapsed and held at this
flow until the end of the run. The injection volume was 10 µL.
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The LC-MS analysis was carried out using a reverse phase column, by which the separation
of the lipids is mostly based on the length of the non-polar acyl- or alkyl-groups in combination
with their degree of unsaturation. Thus, PC and PE species baring PUFA were separated within
small retention times (peaks 1–3), rather than other PC and PE species baring more saturated and
longer chains within their structures that seem to be eluted in higher retention times (peaks 4–9).
More specifically, in the negative ion mode, survey scans between 600 and 1000 m/z of MS1 (Figure 4)
demonstrated a specific pattern of molecular species for PC eluted in peaks 1–3; it is proposed that
many of these are diacyl-glycerol species containing either 14:0, 16:0, 16:1, 18:0, 18:1, or 18:2 fatty acids
at the sn-1 position and mostly either the 22:6 fatty acid (DHA) or the 20:5 fatty acid (EPA) in the sn-2
position. Interestingly, 1-O-alkyl-2-sn-acyl-PC moieties also seem to be present in less, but considerable
quantities, which are outlined in squares in Figure 4. Interestingly, at peak 3c (elution time 3.2 min),
a specific 1-O-alkyl-(18:0)-2-sn-alkyl-(22:6,DHA)-3-PC with theoretical mass of 819.61 (with a relative
demethylated negative ion [M − CH3]− at 805.4 m/z) seems to be present in the TLC fraction of
the bioactive PC of salmon PL. PC species eluted in peaks 4–9, with higher retention times, seem
to have longer and more saturated carbon chains of their acyl-moieties. MS-data of these diacyl-PC
species (with longer and more saturated fatty chains at both the sn-1 and sn-2 positions) are not shown,
since such PC-species do not seem to possess any effect against platelet aggregation and have not been
previously demonstrated to have similar bioactivity.
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Figure 4. Representative mass spectra of PC species present in the relative TLC fraction of bioactive
salmon PC. The LC-MS analysis demonstrated that the TLC fraction of the bioactive salmon PC contains
a mixture of several PC species. (A–C) Mass spectra depicting the most abundant PC molecules eluted
at peaks 1, 2, and 3 of the LC-MS analysis, respectively. The most probable and proposed identities of
the PC species for each acquired m/z values were verified using the LIPID MAPS: Nature Lipidomics
Gateway (www.lipidmaps.org), by using the lowest del a values during identification, in combination
with their content of FA that w s acquir d by both GC-MS and LC-MS analyses. I all 3 peaks,
several PC m lecules are proposed baring either EPA r DHA in the sn-2 position of the glycerol
backbone, whereas lower but considerable quantities of alkyl-acyl moieties also seem to be present
in all spectra (A–C) that are outlined in squares. Interestingly, at peak 3c (elution time 3.2 min),
a 1-O-alkyl (18:0)-2-sn-akyl (22:6, DHA)-3-glycerophosphocholine seems to be present in the TLC
fraction of the bioactive salmon PC. FA: fatty acids; EPA: eicosapentaenoic acid; DHA: docosahexaenoic
acid; PC: phosphatidylcholine.
In th negativ ion mode, survey scans between 600 and 1000 m/z of MS1 (Figure 5) also exhibited
a specific pattern of molecular species for PE; it is proposed that many of these are diacyl-glycerol
species containing either 16:0, 18:0, 20:0 fatty acids at the sn-1 position and mostly the 22:6 (DHA) fatty
acid in the sn-2 position. Interestingly, 1-O-alkyl-2-sn-acyl-PE moieties also seem to be present, yet in
less considerable quantities that are outlined in squares in Figure 5. PE species eluted in peaks 5–6,
with higher retention times, seem to have longer more saturated carbon chains of their acyl-moieties
(data not shown).
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of sever l PE species. (A–C) Mass spectr depicting the most abundant PE molecul s eluted at peaks
1, 3a, and 3b of the LC-MS analysis, respectively. The most probable and proposed identities of PE
species for each acquired m/z values were verified using the LIPID MAPS: Nature Lipidomics Gateway
(www.lipidmaps.org), by using the lowest delta values during identification, in combination with
their content in FA that was acquired by both GC-MS and LC-MS analyses. In all 3 peaks, several PE
molecules are proposed with DHA in the sn-2 position of the glycerol backbone, whereas lower but
considerable quantit es of alkyl-acyl moieties seem to be present only at B and C spectra of the PE
molecules eluted at peak 3, which are outlined in squares. FA: fatty acids; EPA: eicosapentaenoic acid;
DHA: docosahexaenoic acid; PE: phosphatidylethanolamine.
3. Discussion
Marine oils have exhibited strong cardioprotective properti as has been extensively
reviewed [24]. Thus, several dietary guidelines (i.e., The US Dietary Guidelines) and healthy
dietary patterns (i.e., the Mediterranean diet) recommend fish intake at least twice weekly [3,11,25].
Intake of farmed Atlantic salmon twice weekly influences lipoprotein particle size, decreases serum
concentrations of triglycerides, and increases HDL cholesterol in a manner associated with CVD risk
reduction [26,27]. It has also been proposed that salmon may possess natural resistance mechanisms to
reduce its own risk of atherosclerosis and cardiovascular risk, which corresponds well with its high
investment in its own lipid metabolism and lipid profile [28]. In addition, oven baking salmon does not
decrease theω3 PUFA contents, indicating that baking salmon is an acceptable means of preparation
that does not alter the potential health benefits of highω3 seafood consumption [29]. Epidemiologic
Mar. Drugs 2018, 16, 176 11 of 19
studies have shown that high dietary consumption of salmon and other oily fish, such as herring and
trout, is associated with reduced rates of myocardial infarction, atherosclerosis, and other ischemic
pathologies. In addition, dietary fish oil induces changes in cardiac function that might contribute to
cardiovascular health benefits in humans and does so by modifying cardiac membranes within a dose
range achievable in the human diet [30].
The therapeutic dose of ω3 fatty acids depend not only in the degree of severity of disease [2],
but also in the form that these essential lipids are consumed with different digestion mechanisms
and bioavailability in cell membranes and lipoproteins [3]. Furthermore, the results of very recent
systematic reviews and meta-analyses have highlighted the lack of evidence to support the routine use
of ω3 PUFA, especially when administered as triglycerides or esters, in the primary and secondary
prevention of inflammatory disorders, since the beneficial effect of fish intake is likely to be mediated
through the interplay of a wide range of nutrients abundant in fish [31–35]. It is now well-established
that more complex mechanisms underlie the beneficial effects of fish/fish-oil consumption and
administration of marine products that go far beyond theω3 PUFA/eicosanoid-related mechanisms [3].
Other lipid constituents are also present in fish and fish oils that have different metabolic effects with
distinct biological activities following absorption [3] and these lipid constituents are the focal point of
the present manuscript.
Marine PL and especially marine phospholipids are gaining significant interest due to their
plethora of beneficial bioactivities [3,11,12]. Dietary phospholipids have physiological functions that
are different to dietary triglycerides. They can provide energy, they are a rich source of PUFA, and
provide major components of cell membranes and plasma lipoproteins, thus they are important in
nutrition and signal transduction for metabolic regulation, and the maintenance of living cells [3,36,37].
Marine phospholipids have a far superior incorporation into plasma lipoproteins including HDL and
cell membranes following their consumption, but they may also provide a much higher bioavailability
of theirω3 fatty acids, which are contained within their unique structures [3]. Additionally, marine
PL have exhibited strong antithrombotic activities through specific mechanisms, including the potent
inhibition of the PAF inflammatory pathway and the modulation of its metabolism towards homeostatic
equilibration of PAF levels [3,4,11–13,16–18]. Through such bioactivities, marine PL have exhibited
potent in vitro and in vivo anti-atherogenic and cardioprotective effects [3,4,11–13,16–18].
In the present study, it was found for the first time that Irish organic farmed salmon contain PL
with potent antithrombotic effects against both the PAF pathway and thrombin pathway of human
platelet aggregation. The in vitro anti-PAF effects of salmon PL are comparable with similar studies
of PL from other fish species, such as sardines, sea bass, sea bream, cod, etc. [3,4,13,16–19]. However,
although still very beneficial, the in vitro anti-thrombin effects of salmon PL were found to be much
less potent (one order of magnitude lower) than their anti-PAF effects on human platelet aggregation,
demonstrating that the TPL extracts of salmon contains PL that interact mostly via the PAF pathway.
In order to elucidate the relationship between the structure/activity of salmon PL, the salmon
TPL extracts were separated by TLC analysis and all subclasses of PL in the TLC fractions obtained
were further tested towards the PAF pathway, while further GC-MS and LC-MS analyses of the most
bioactive PL subclasses were also conducted. It was found that specific lipid subclasses obtained
by the TLC analysis of the salmon TPL, which correspond to PC and PE, exhibited the most potent
inhibitory effect towards the PAF-induced human platelet aggregation, with respect to all the other
lipid subclasses tested. These results are also in accordance with our groups previous studies of the
equivalent TLC lipid subclasses of PC and PE in other fish species [15–17].
Since PAF is a potent inflammatory mediator that is implicated in several chronic diseases
including atherosclerosis and CVD [7], renal disorders [38], cancer [5], HIV infection [39], etc., the novel
findings of this study concerning the potent anti-PAF activities of salmon polar lipids seems to provide
additional mechanistic evidence for the beneficial outcomes of the dietary intake of salmon and/or
salmon oil in such disorders.
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Concerning the fatty acid profile of these Irish organic farmed salmon PL, it was found that
they contain high levels of ω3 PUFA, with the most abundant ω3 fatty acids being EPA and DHA.
Furthermore, theω3 fatty acid content was significantly higher than that ofω6 fatty acids, and thus
the ratio ofω6/ω3 PUFA was found to be approximately 1/2.5. This fatty acid profile is comparable
to previously reported salmon lipid profiles [40–42].
In addition, the fatty acid profile of the salmon PC and PE lipid subclasses, obtained by the TLC
analysis of the salmon TPL, were also abundant inω3 PUFA, with PC baring higher content of both
EPA and DHA. The relative ratio ofω6/ω3 PUFA in these salmon PL was found to be approximately
1/5 and 1/1.5, respectively for salmon PC and PE.
Thus, the ratio ofω6/ω3 PUFA of salmon TPL, salmon PC, and salmon PE was found to be not
only lower than the intermediate relative ratio of 1/1, but also much lower than that of Westernised
diets, which is within the range of 5/1–20/1 [2]. It has been reported that high values of this ratio, which
is observed mostly in Westernised diets are also correlated with a higher risk of chronic diseases [2,43].
Taking into account that marine PL possess high ability to incorporate in plasma lipoproteins and
cell membranes and have high bioavailability of theirω3 PUFA [3], the much lower ratio ofω6/ω3
PUFA observed in salmon PL may also provide further evidence for their potential cardioprotective
properties, since the lower this ratio is in the diet, the better health outcomes it provides against such
chronic diseases [2].
Furthermore, by applying LC-MS analysis it is proposed that the PC species of the most bioactive
TLC fractions of salmon PL (Figure 4) seem to contain both DHA and EPA at the sn-2 position, while
the PE species seem to contain mostly DHA at the sn-2 position of their glycerol backbone (Figure 5).
Such PL upon intake can be directly absorbed through the intestine as 20% of phospholipids from food
intake are absorbed directly through intestine to blood and incorporated into blood lipoproteins [3].
Furthermore, phospholipids can be taken up/endocytosed by several cells with normal mechanisms,
where upon phospholipase A2 (PLA2) activities allow the liberation of free DHA and EPA fatty
acid from their sn-2 position, which can inhibit platelet activation with specific pathways but also
through unknown mechanisms, especially for DHA [44]. Thus, these salmon PL that are rich in ω3
PUFA that are present mostly at the sn-2 position of the glycerol backbone, can serve as precursors
(pro-drugs) of theω3 PUFA that in their free fatty acid form have exhibited much higher anti-PAF and
cardioprotective activities than their usually prescribed form as methyl esters [15].
In general, various PL in several foods have been found to exhibit either a weak agonistic
(aggregatory) or an inhibitory effect on PAF-induced biological activities [3]. Some lipids, at low
levels, could have a rather weak agonistic effect, but at higher levels their inhibitory activities prevail.
Some other lipids might not show any agonistic activities but only inhibitory activities. The most
classic PAF agonists are several alkyl-acyl-phospholipids [45]. In this study, LC-MS analysis revealed
that considerable amounts of both alkyl-acyl-PC and alkyl-acyl-PE species are present in salmon PL.
However, no aggregatory agonistic effect towards PAF was observed in all the PL tested. It seems that
these molecules possess greater inhibitory effects against the PAF pathway than any possible agonistic
effect from the constituent lipids in the PL fractions, and in this case, these components are practically
acting mostly as PAF inhibitors.
Interestingly, at peak 3c (elution time 3.2 min) of the HPLC analysis of the PC subclasses, a specific
1-O-alkyl-(18:0)-2-sn-akyl-(22:6, DHA)-3-PC, with theoretical mass of 819.61 (with a relative demethylated
negative ion [M − CH3]− at 805,4 m/z) seems to be present in the PC TLC fraction of the salmon, which
was bioactive against PAF. Taking into account that these fatty moieties seem to be present in this
molecule and were also found within the most abundant molecules (18:0 fatty acid of the saturated ones
and DHA (22:6) of the PUFA), by both GC-MS analyses (see Table 3) and LC-MS analyses of the salmon
PL, this finding is in accordance with previously reported results of other bioactive lipid fractions in
another fish species [15], where it was also found that the lipid composition of these bioactive fractions
contained various glycerophospholipid species, where the majority of them have either 18:0 or 18:1 fatty
acids in the sn-1 position and either 22:6 or 20:2 fatty acids in the sn-2 position.
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It seems that the copresence of the DHA ω3 PUFA at the sn-2 position of such alkyl-acyl-
phospholipids gives them higher inhibitory effects than any agonistic effect against PAF. Moreover,
weak PAF agonists (with very low aggregatory activity; several orders of magnitude less than PAF) have
been found to exhibit higher antiatherogenic activity than PAF inhibitors in vivo [13,46]. The presence
of PL in PC and PE fractions that exhibit strong inhibitory effects against PAF-induced platelet
aggregation is a potent indication that these salmon PL fractions contain biologically active compounds
against PAF and consequently against atherogenesis and CVD. This means that unlike many other
sources of lipids, Irish organic farmed salmon seem to be an excellent source of molecules with strong
inhibitory effects against PAF.
Furthermore, salmon PC and in general marine PL baring ω3 PUFA and MUFA within their
structures, have exhibited beneficial effects in several disorders through pleiotropic activities [3,37].
For example, salmonω3 PUFA PC prevents the development of obesity related diseases through the
suppression of lipogenic gene expression and the enhancement of lypolytic gene expression in the
liver of obese rats [36]. In addition, salmonω3 PUFA PC have also exhibited beneficial effects in the
treatment of chronic liver diseases through its anti-inflammatory activities [47]. Administration of
marineω3 PUFA PC (i.e., PC from squid rich in DHA and PC from starfish rich in EPA) were shown
to inhibit the growth of chemically induced colon cancer in vitro [48], while when administration of
marine ω3 PUFA PC was combined with other marine phospholipids, the anti-cancer outcome in
Caco-2 tumours was more potent [49]. Marine PL containing predominantly EPA and DHA were also
shown to have remarkable lipid-lowering effects (reduction of total cholesterol, LDL, and triglyceride
levels, while HDL increased significantly), while the supplementation of traditional fish oil (FA mostly
bound to the triglyceride instead of PL) lowers only blood triglyceride levels and seems to have no
effect on LDL and HDL levels [3,37]. It should be noted that most of these studies have been performed
in vitro or in vivo and only limited evidence is available for the benefit of marine PL supplementation
in humans [3,37], thus further research is required.
4. Materials and Methods
4.1. Materials and Instrumentation
All glass and plastic consumables, reagents, and solvents were of analytical grade and were
purchased from Fisher Scientific Ltd. (Dublin, Ireland). 20 G safety needles and evacuated sodium
citrate S-monovettes for blood sampling were purchased from Sarstedt Ltd. (Wexford, Ireland).
The preparative TLC glass plates (20 × 20 cm) with silica gel G-60 of 1.0/2.0 mm thickness were
purchased from Merck (Darmstadt, Germany). Bioassays on hPRP aggregations were carried out on
a Chronolog-490 two channel turbidimetric platelet aggregometer (Havertown, PA, USA), coupled
to the accompanying AGGRO/LINK software package. All platelet aggregation consumables were
purchased from Labmedics LLP (Abingdon on Thames, UK). Standard PAF, thrombin and BSA were
purchased from Sigma Aldrich (Wicklow, Ireland). Centrifugations were carried out on an Eppendorf
5702R centrifuge (Eppendorf Ltd., Stevenage, UK). Spectrophotometric analysis was carried out on
a Shimadzu UV-1800 spectrophotometer (Kyoto, Japan). All GC-MS consumables were purchased
from Apex Scientific Ltd. (Kildare, Ireland). Fatty acid methyl esters (FAME) standards for the GC-MS
analysis and the egg phospholipid standard were purchased from Sigma Aldrich, Wicklow, Ireland.
The GC-MS was a Varian 431-GC couples to a Varian 210-MS accompanied with the Varian Star
Chromatography Workstation Version 6 software (Agilent Technologies, Palo Alto, CA, USA) and a
NIST library (Gaithersburg, MD, USA).
4.2. Isolation of Salmon Total Lipids, Total Polar, and Total Neutral Lipids
Several (n = 6) 100 g samples of organic fresh farmed salmon fillets donated by Marine Harvest
(private company), were homogenised and their total lipids (TL) were extracted into chloroform
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according to the method of Bligh and Dyer [50], flash vaporised under N2 stream, weighed, re-dissolved
in 2 mL of CHCl3/MeOH 1:1 v/v, and stored at −20 ◦C.
One tenth of the TL was stored in sealed vials at −20 ◦C, while the rest was further separated into
the total neutral lipids (TNL) fraction and the total polar lipids (TPL) fraction by the counter-current
distribution method of Galanos and Kapoulas [51]. The acquired TNL and TPL fractions were weighed
and stored under a nitrogen atmosphere at −20 ◦C for further analysis.
4.3. Fractionation of Salmon TPL by Thin-Layer Chromatography
The TLC analysis of the salmon TPL was performed as previously described for other fish species
using an egg phospholipid standard (Sigma Aldrich, Wicklow, Ireland) [17]. Briefly, a gradient of
approximately 10–100 mg of TPL was applied to the TLC plates. An elution system consisting of
chloroform:methanol:water 65:35:6 (v/v/v), was utilised for the separation of TPL. Subsequently
the plates were stained under iodine vapours. Six major bands appeared after the separation of the
salmon TPL. Following the evaporation of the iodine vapours, the bands were scraped, and lipids
were extracted from the silica gel according to the Bligh and Dyer method [50]. The chloroform
phase was evaporated to dryness under nitrogen and lipids were weighed, re-dissolved in 1 mL of
chloroform:methanol 1:1 (v/v), and stored at −20 ◦C in nitrogen until further analysis.
4.4. Human Platelet-Rich Plasma (hPRP) Aggregation Studies of Salmon Polar Lipids
The hPRP was separated as previously described [52] with some modifications. Briefly, for hPRP
isolation, healthy human volunteers (n = 10) donated fasting blood samples. The Ethics Committee
of the University of Limerick approved the protocol and it was performed in accordance with the
Declaration of Helsinki. Healthy donors were fully aware that their blood samples were used in
our study and written consent was provided to the specialised phlebotomist. A total of 50 mL of
blood was collected from the median cubital vein or cephalic vein of each healthy volunteer via
venepuncture using a 20 G safety needle, and blood was drawn into sodium citrate anticoagulant
S-monovettes using the aspiration method (0.106 mol/L in a 1:10 ratio of citrate to blood; Sarstedt Ltd.,
Wexford, Ireland). The collected blood samples were centrifuged at 194 g for 18 min at 24 ◦C with
no brake applied. The supernatant hPRP was then transferred to polypropylene tubes at room
temperature for the aggregation bioassays, whereas platelet-poor plasma (PPP) was obtained by
further centrifuging the specimens at 1465 g for 20 min 24 ◦C with no brake applied. hPRP was
adjusted to 500,000 platelets/mL if required by addition of the respective volume of PPP according to
the absorbance of the hPRP measured in the spectrophotometer. All procedures took place at 24 ◦C
and all analyses were carried out within 2.5 h of the initial blood draw. PRP was stored at 24 ◦C before
use in platelet aggregation bioassays.
Aliquots of standard PAF solution in chloroform/methanol (1:1 v/v) were evaporated under a
stream of nitrogen and re-dissolved in BSA (2.5 mg BSA/mL saline) to obtain PAF solutions with
final concentrations in the cuvette ranging from 2.6 × 10−8 to 2.6 × 10−5 mol/L. The examined
salmon PL samples were also dissolved in BSA (2.5 mg BSA/mL saline). Standard active thrombin
was dissolved in saline prior to testing. The ability of each selected sample to cause inhibition
of either PAF-induced or thrombin-induced platelet aggregation was studied by adding various
concentrations of each sample into the platelet suspension. Prior to testing, 250 µL of hPRP was
added to an aggregometer cuvette at 37 ◦C with stirring at 1000 rpm and was calibrated using the
PPP as a blank. The maximum-reversible PAF-induced/thrombin-induced platelet aggregation was
determined as 100% aggregation, that was also used as baseline (0% inhibition), by adding PAF
at approximately 2.6 × 10−8 M final concentration in the cuvette or thrombin at approximately
0.01–0.04 U/mL in the cuvette. The PAF-induced/thrombin-induced aggregation was calculated
first at 0% inhibition of baseline in a cuvette, whereas after the preincubation of hPRP with the test
samples in a variety of concentrations in a different cuvette, the same amount of PAF/thrombin was
added and the reduced aggregation was calculated. Thus, a linear curve at the 20–80% range of
Mar. Drugs 2018, 16, 176 15 of 19
the percentage of inhibition against PAF-induced/thrombin-induced aggregation of hPRP to the
concentrations of each sample was deduced. From this curve, the concentration of the sample
that led to 50% of PAF-induced/thrombin-induced aggregation of hPRP was calculated as the 50%
inhibitory concentration value, also known as the IC50 value, for each sample. All experiments were
performed in triplicate (n = 3), using a different donor’s blood sample for each replicate, to ensure
reproducibility. The resulting IC50 values were expressed as a mean value of the mass of lipid (µg) in
the cuvette ± standard deviation (SD).
4.5. GC-MS Analysis of Salmon Polar Lipids
Fatty acid methyl esters of salmon TPL and the PL subclasses of the PC and PE, which were
obtained by the TLC analysis of salmon TPL, were prepared using a solution 0.5 N KOH in 90%
CH3OH and extracted with n-hexane as previously described [53]. The fatty acid analysis was carried
out using the internal standard method as previously described [22,53], with some modifications.
In brief, a five-point calibration curve was prepared using five solutions of heptadecanoic acid methyl
esters (17:0—50 ppm, 100 ppm, 200 ppm, 400 ppm, 800 ppm) and heneicosanoic acid (21:0—five
500 ppm injections) methyl esters standards. Five 1 µL injections of each solution were analysed with a
Varian 410-Gas Chromatographer coupled to a Varian 210-MS detector equipped with a split/splitless
injector (Agilent Technologies, Palo Alto, CA, USA). The ratio of the mean is of heptadecanoic acid
(17:0) to that of the internal standard (21:0) and is used as the y-axis variable, whereas the concentration
(ppm) of 17:0 is used as the x-axis variable of the calibration curve. The equation that described the
curve was: y = 0.0041x + 0.12 with an R2 = 0.9969, where the ratio of the area of the analyte peak to
that of the internal standard represents the y value for the above equation, subsequently the x-value
represents the analyte concentration of a selected fatty acid in the lipid sample to be tested.
Separation of the FAME was achieved on an Agilent J&W DB-23 fused silica capillary column
(60 m, 0.25 mm, i.d., 0.25 µm; Agilent, Santa Clara, CA, USA). The injector was set at 230 ◦C with a
split ratio of 1:5; the injection volume was 1 µL. The carrier gas was high purity helium with a liner
flow rate of 1 mL/min. The oven temperature was initially programmed to 100 ◦C for 5 min, raised
to 240 ◦C at 3 ◦C/min, and finally isothermal at 240 ◦C for 10 min. FAME were identified using a
pre-derivatised 37-component FAME standards mix (Sigma Aldrich, Wicklow, Ireland) by comparison
of the retention times and their subsequent obtained MS spectra of the relative peaks with the aid of
the Varian Star Chromatography Workstation Version 6 software (Agilent Technologies, Palo Alto, CA,
USA) and a NIST library (Gaithersburg, MD, USA).
4.6. LC-MS Analysis of Salmon Polar Lipids
The salmon TPL and the most bioactive TLC fractions against the PAF pathway, PC and PE, were
further analysed by LC-MS. Each of these lipid samples was separated in two half parts and dried
in N2 stream. The first half part of each sample was saponified by adding 1.5 mL of saponification
reagent, [2.5 M KOH: methanol (1:4, v/v)], which was gently vortexed. The vials were incubated at
72 ◦C for 15 min prior to addition of 225 µL of formic acid. Then, 1725 µL of chloroform and 375 µL
of Milli-Q water was added, and vortexed to separate two layers. The chloroform layer containing
free fatty acids was transferred carefully to amber vials and evaporated to dryness before storing at
−20 ◦C until LC-MS analysis as per method described earlier [54].
Before LC-MS analysis, all the dried lipids were re-constituted in 500 µL of methanol:
dichloromethane (2:1 v/v), centrifuged at 13,000 rpm for 6 min prior to filtering through 3 kDa
ultra-centrifuge filters (Amicon Ultra 3k). Polar lipid and free fatty acid profiles were obtained in a
HPLC (Agilent 1260 series) equipped with a Q-TOF mass spectrometer (Agilent 6520) and the source
type was ESI. The column used for separations was an Agilent C18 Poroshell 120 column (2.7 µm,
3.0 × 150 mm). The composition of the mobile phase (A) was 2 mM ammonium acetate in water and
2 mM ammonium acetate in 95% acetonitrile for mobile phase (B). Chromatographic separation was
performed by gradient elution starting with 60% B for 1 min, then increasing to 90% B over 2.5 min.
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Subsequently, 90% B was held for 1.5 min and increasing afterward to 100% over 5 min. Then, 100% B
was held for 4 min, reducing afterward to 60% B over 0.5 min and hold for 1 min until the next run.
The mobile phase flow rate was 0.3 mL/min until 5 min elapsed, increasing up to 0.6 mL/min after
10 min and held at this flow rate until the end of the run. The injection volume was 10 µL. The mass
spectrometer was operated in negative ionization mode, scanning the lipids from m/z 50–1100. Drying
gas flow rate, temperature, and nebuliser pressure were at 5 L min−1, 325 ◦C, and 30 psi, respectively.
Fragmentor and skimmer voltages were kept at 175 V and 65 V, respectively, and the capillary voltage
was 3500 V. In the negative ion mode, the monitoring reference masses used were 1033.988 and 112.9855,
respectively. Assignment of free fatty acids and phospholipid species is based upon a combination of
survey, daughter, precursor, and neutral loss scans. The identity of phospholipid species were verified
using the LIPID MAPS: Nature Lipidomics Gateway (www.lipidmaps.org), by using the lowest delta
values combined with the results obtained from the LC-MS analysis of FFA and the GC-MS analysis
of FAME.
5. Conclusions
For the first time it has been demonstrated that salmon PL have the potential to inhibit platelet
aggregation through their inhibitory effects on both the PAF and thrombin pathways. Their anti-PAF
effects were found to be much higher than that of their anti-thrombin effects. These results emphasise
the high quality of Irish organic farmed salmon fillets and their PL content with respect to protection
from thrombosis. It is of interest to determine whether both the physiological and the beneficial
effects of marine PL are the result of their polar head groups, the constituting PUFA (especially those
incorporated at the sn-2 position), or both in combination. Since PUFA PL from other fish species
also possess beneficial bioactivities [3,15], we believe that it is the coexistence of both these structural
elements within the structures of marine PL that gives them the potential to exhibit pleiotropic
beneficial effects in several chronic disorders [3,8]. Nevertheless, because of the extreme complexity in
the aetiology of CVD and chronic inflammatory diseases, the best strategy could be to fully monitor
the main features and effects of dietary patterns associated with a low prevalence and risk of such
disorders. In such diets, including the Mediterranean diet, consumption of oily fish (e.g., sardines) rich
in bioactive PL seems to be a major constituent and a key food. Salmon is a very worthy candidate to
be incorporated into modern dietary patterns, as oily fish contain bioactive PL that prevent thrombosis.
Our current and future work aims to identify and elucidate the cardioprotective structures
and mechanisms of fish PL that inhibit atherosclerosis, by applying a novel pro-drug/precursor
approach [55] and by exploiting phospholipids containingω3 PUFA within their structure, in order to
reduce and inhibit the inflammatory and thrombotic PAF activity.
However, further ex vivo and in vivo studies are required in order to elucidate the
structure/function relationship of salmon PL, their beneficial bioactivities, and their potential use as
food supplements and nutraceuticals.
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